Posters

Accelerated corneal cross-linking using a Riboflavin solution with HPMC instead of Dextran

Poster Details

First Author: N.Pircher AUSTRIA

Co Author(s):    A. Gschliesser   S. Pieh   G. Schmidinger              

Abstract Details

Purpose:

To evaluate the effect of accelerated corneal crosslinking (CXL) with the UV-X 2000 device in combination with a dextran-free riboflavin solution (Vibex-Rapid, Avedro). This solution guarantees stable pachymetry readings and reduced treatment times.

Setting:

Department of Ophtalmology, Medical University of Vienna

Methods:

20 eyes of 20 patients that underwent accelerated CXL (10 minutes irradiation time, 9mW/cm2) were analysed. Mean keratometric values were measured using the “Power Distribution Display” software tool (Oculus GmbH) in a 2mm diameter circular zone in the center of the cornea (K2c) and in the area around the maximum K-value (K2max). The depth of the central demarcation line (Dc) was also assessed one month after CXL using an anterior segment OCT device (Visante OCT, Zeiss). Further, Kmax, CDVA and pachymetric values were also evaluated. Patients were followed up preoperatively and 1, 3 and 6 months postoperatively.

Results:

Mean K2c decreased from 50.42 ± 6.08 D before CXL to 49.83 ± 6.17 D after 6 months. Mean K2max showed a slight decrease at the 6 months follow-up visit from 56.58 ± 6.63 D to 55.98 ± 6.67 D. Mean Kmax decreased from 59.05 ± 8.62 D preoperatively to 58.10 ± 7.88 D. The mean pachymetric value of the thinnest point of the cornea was 454µm ± 43µm before CXL and 448µm ± 42µm after 6 months. The mean depth of the demarcation line was 164 µm ± 85 µm. CDVA improved after 6 months (∆ 0.08 logMAR).

Conclusions:

According to current laboratory studies the Bunsen-Roscoe law may not be applicable in corneal crosslinking. Nevertheless, recently publicised studies showed comparable effects of “Accelerated CXL” and the Standard Dresden Protocol. Despite a remarkable variance in the depth of the postoperative Demarcation line the clinical results seem to be the same as for CXL according to the Standard Dresden Protocol.

Financial Disclosure:

NONE